GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Other Cash Payments from Operating Activities

ACHFF (Arch Biopartners) Other Cash Payments from Operating Activities : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Arch Biopartners Other Cash Payments from Operating Activities?

Arch Biopartners's Other Cash Payments from Operating Activities for the three months ended in Mar. 2025 was $0.00 Mil.

Arch Biopartners's Other Cash Payments from Operating Activities for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.


Arch Biopartners Other Cash Payments from Operating Activities Historical Data

The historical data trend for Arch Biopartners's Other Cash Payments from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Other Cash Payments from Operating Activities Chart

Arch Biopartners Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Other Cash Payments from Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arch Biopartners Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Other Cash Payments from Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Arch Biopartners Other Cash Payments from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Other Cash Payments from Operating Activities represents cash flow paid from other operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Other Cash Payments from Operating Activities for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Biopartners Other Cash Payments from Operating Activities Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Other Cash Payments from Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Other Cash Payments from Operating Activities
Traded in Other Exchanges
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.

Arch Biopartners Headlines

From GuruFocus